NEW YORK (GenomeWeb News) – Proteome Sciences and the Moffitt Cancer Center have struck a partnership to research ways to develop assays that can be adapted for analyzing tumors, the UK-based company said today.
Proteome Sciences said it will work with Moffitt, located in Tampa, Fla., to develop mass spectrometry assays that can measure important signalling and repair pathway proteins for use in tumor biopsy analysis in the clinic.
Moffitt Principal Investigator John Koomen said in a statement that the collaboration will enable his lab to "incorporate a large number of key proteins and post-translational modifications to rapidly translate laboratory tests into the direct management of cancer patients. We believe that knowledge of the molecular switches operating within each individual tumor will allow better selection and monitoring of treatment efficacy."
"There has been tremendous progress in the ability of mass spectrometers to selectively measure subtle changes in the proteins involved in cellular signalling and repair," added Proteome Sciences COO Ian Pike. "New methods capable of simultaneously measuring these changes across several pathways are urgently needed to deliver better outcomes in all cancers," Pike said.
Proteome Sciences is based in Cobham, UK, and it operates research services facilities in London and Frankfurt. The firm's biomarker services use tandem mass tag workflows to develop biomarker-based assays.